Linaclotide Dosage and Efficacy

Clinical Evidence

• The 290 mcg dose of linaclotide has been extensively studied in IBS-C patients, showing significant improvements in abdominal pain and constipation symptoms 1, 2, 3
• Linaclotide 290 mcg once daily demonstrated significant improvement in both abdominal pain/discomfort scores and increased complete spontaneous bowel movements (CSBMs) 4, 5
• Diarrhea is the most common adverse event, occurring in approximately 16.3% of patients receiving linaclotide compared to 2.3% with placebo, with a discontinuation rate of about 3.4% due to diarrhea 6

Guideline Recommendations

• The American Gastroenterological Association has issued a strong recommendation for using linaclotide in patients with IBS-C, citing high certainty in the evidence of effects 7, 6